The Korea Superconducting Tokamak Advanced Research (KSTAR) project is the major effort of the national fusion programme of the Republic of Korea. Its aim is to develop a steady state capable advanced superconducting tokamak to establish a scientific and technological basis for an attractive fusion reactor. The major parameters of the tokamak are: major radius 1.8 m, minor radius 0.5 m, toroidal field 3.5 T and plasma current 2 MA, with a strongly shaped plasma cross-section and double null divertor. The initial pulse length provided by the poloidal magnet system is 20 s, but the pulse length can be increased to 300 s through non-inductive current drive. The plasma heating and current drive system consists of neutral beams, ion cyclotron waves, lower hybrid waves and electron cyclotron waves for flexible profile control in advanced tokamak operating modes. A comprehensive set of diagnostics is planned for plasma control, performance evaluation and physics understanding. The project has completed its conceptual design and moved to the engineering design and construction phase. The target date for the first plasma is 2002.

No abstract

No abstract

Cell-tracking methods with molecular-imaging modality can monitor the biodistribution of cells. In this study, the direct-labeling method with 64 Cu-pyruvaldehyde-bis(N4-methylthiosemicarbazone) ( 64 Cu-PTSM), indirect cell-labeling methods with herpes simplex virus type 1-thymidine kinase (HSV1-tk)-mediated 124 I-2¢-fluoro-2¢-deoxy-1-b-d-arabinofuranosyl-5-iodouracil ( 124 I-FIAU) were comparatively investigated in vitro and in vivo for tracking of human chronic myelogenous leukemia cells. K562-TL was established by retroviral transduction of the HSV1-tk and firefly luciferase gene in the K562 cell. K562-TL cells were labeled with 64 Cu-PTSM or 124 I-FIAU. Cell labeling efficiency, viability, and radiolabels retention were compared in vitro. The biodistribution of radiolabeled K562-TL cells with each radiolabel and small-animal positron emission tomography imaging were performed. Additionally, in vivo and ex vivo bioluminescence imaging (BLI) and tissue reverse transcriptasepolymerase chain reaction (RT-PCR) analysis were used for confirming those results. K562-TL cells were efficiently labeled with both radiolabels. The radiolabel retention (%) of 124 I-FIAU (95.2% -1.1%) was fourfold higher than 64 Cu-PTSM (23.6% -0.7%) at 24 hours postlabeling. Viability of radiolabeled cells was statistically nonsignificant between 124 I-FIAU and 64 Cu-PTSM. The radioactivity of each radiolabeled cells was predominantly accumulated in the lungs and liver at 2 hours. Both the radioactivity of 64 Cu-PTSM-and 124 I-FIAU-labeled cells was highly accumulated in the liver at 24 hours. However, the radioactivity of 124 I-FIAU-labeled cells was markedly decreased from the body at 24 hours. The K562-TL cells were dominantly localized in the lungs and liver, which also verified by BLI and RT-PCR analysis at 2 and 24 hours postinjection. The 64 Cu-PTSM-labeled cell-tracking method is more efficient than 124 I-FIAU-labeled cell tracking, because of markedly decrease of radioactivity and fast efflux of 124 I-FIAU in vivo. In spite of a high labeling yield and radiolabel retention of 124 I-FIAU in vitro, the in vivo cell-tracking method using 64 Cu-PTSM could be a useful method to evaluate the distribution and targeting of various cell types, especially, stem cells and immune cells.

For the successful clinical advancement of exosome therapeutics, the biodistribution and pharmacokinetic profile of exogenous exosomes in various animal models must be determined. Compared with fluorescence or bioluminescence imaging, radionuclide imaging confers multiple advantages for the in vivo tracking of biomolecular therapeutics because of its excellent sensitivity for deep tissue imaging and potential for quantitative measurement. Herein, we assessed the quantitative biodistribution and pharmacokinetics of good manufacturing practice-grade therapeutic exosomes labeled with zirconium-89 (89Zr) after systemic intravenous administration in mice and rats. Quantitative biodistribution analysis by positron emission tomography/computed tomography and gamma counting in mice and rats revealed that the total 89Zr signals in the organs were lower in rats than in mice, suggesting a higher excretion rate of exosomes in rats. A prolonged 89Zr signal for up to 7 days in most organs indicated that substantial amounts of exosomes were taken up by the parenchymal cells in those organs, highlighting the therapeutic potential of exosomes for the intracellular delivery of therapeutics. Exosomes were mainly distributed in the liver and to a lesser extent in the spleen, while a moderately distributed in the kidney, lung, stomach, intestine, urinary bladder, brain, and heart. Exosomes were rapidly cleared from the blood circulation, with a rate greater than that of free 89Zr, indicating that exosomes might be rapidly taken up by cells and tissues.

This paper presents a two-step, semi-automated method for reconstructing a three-dimensional (3D) shape of the prostate from a 3D transrectal ultrasound (TRUS) image. While the method has been developed for prostate ultrasound imaging, it can potentially be applicable to any other organ of the body and other imaging modalities. The proposed method takes as input a 3D TRUS image and generates a watertight 3D surface model of the prostate. In the first step, the system lets the user visualize and navigate through the input volumetric image by displaying cross sectional views oriented in arbitrary directions. The user then draws partial/full contours on selected cross sectional views. In the second step, the method automatically generates a watertight 3D surface of the prostate by fitting a deformable spherical template to the set of user-specified contours. Since the method allows the user to select the best cross-sectional directions and draw only clearly recognizable partial or full contours, the user can avoid time-consuming and inaccurate guesswork on where prostate contours are located. By avoiding the usage of noisy, incomprehensible portions of the TRUS image, the proposed method yields more accurate prostate shapes than conventional methods that demand complete cross-sectional contours selected manually, or automatically using an image processing tool. Our experiments confirmed that a 3D watertight surface of the prostate can be generated within five minutes even from a volumetric image with a high level of speckles and shadow noises.

A miniature hybrid plasma focus device, operated in xenon gas medium and driven by a 10kA fast current pulse, has been used to generate extreme ultraviolet radiation in the range of 6–15nm. At present the radiation characteristics from xenon plasma were mainly assessed qualitatively using standard tools such as visible light framing camera, extreme ultraviolet (EUV) pinhole camera, and EUV photodiode. Strong pinching of xenon plasma is indicative from both visible and EUV imagings. The maximum size of the EUV emitting zone is estimated to be of the order of 0.21×1.55mm and the estimated value is within the accepted value as benchmarked by industries. The EUV intensity measurement by photodiode showed fairly isotropic radiation at least in a half solid angle. This device can be developed further as a competent source for EUV metrology or lithography applications.

Purpose This study aimed to develop a gene expression targeting method for specific imaging and therapy of alpha-fetoprotein (AFP)-producing hepatocellular carcinoma (HCC) cells, using an adenovirus vector containing the human sodium/iodide symporter (hNIS) gene driven by an AFP enhancer/promoter. Methods The recombinant adenovirus vector, AdAFPhNIS (containing the hNIS gene driven by human AFP enhancer/ promoter) was prepared. After in vitro infection by the adenovirus, hNIS gene expression in AFP-producing cells and in AFP-nonproducing cells was investigated using 125 I uptake assay and semi-quantitative reverse transcription polymerase chain reaction (RT-PCR). The killing effect of 131 I on AdAFPhNIS-infected HCC cells was studied using an in vitro clonogenic assay. In addition, tumor-bearing mice were intravenously injected with the adenovirus, and scintigraphic images were obtained. Results The expression of hNIS was efficiently demonstrated by 125 I uptake assay in AFP-producing cells, but not in AFP-nonproducing cells. AFP-producing HCC-targeted gene expression was confirmed at the mRNA level. Furthermore, in vitro clonogenic assay showed that hNIS gene expression induced by AdAFPhNIS infection in AFPproducing cells caused more sensitivity to 131 I than that in AFP-nonproducing cells. Injected intravenously in HuH-7 tumor xenografts mice by adenovirus, the functional hNIS gene expression was confirmed in tumor by in vivo scintigraphic imaging. Conclusions An AFP-producing HCC was targeted with an adenovirus vector containing the hNIS gene using the AFP enhancer/promoter in vitro and in vivo. These findings demonstrate that AFP-producing HCC-specific molecular imaging and radionuclide gene therapy are feasible using this recombinant adenovirus vector system.